Premium
Genome editing in induced pluripotent stem cells
Author(s) -
Cheng LiTao,
Sun LiangTso,
Tada Takashi
Publication year - 2012
Publication title -
genes to cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.912
H-Index - 115
eISSN - 1365-2443
pISSN - 1356-9597
DOI - 10.1111/j.1365-2443.2012.01599.x
Subject(s) - biology , induced pluripotent stem cell , genome editing , transcription activator like effector nuclease , zinc finger nuclease , homologous recombination , genome , genetics , embryonic stem cell , effector , regenerative medicine , stem cell , computational biology , microbiology and biotechnology , gene
The discovery of induced pluripotent stem (iPS) cells has broadened the promises of regenerative medicine through the generation of syngeneic replacement cells or tissues via the differentiation of patient‐specific iPS cells. To apply iPS cell‐mediated therapy to patients with genetic disorders, however, genome‐editing technologies with high efficiency and specificity are needed. Recently, several targeted genome‐editing strategies mediated by zinc finger nuclease and transcription activator‐like effector nuclease have been applied to human and mouse iPS cells. Furthermore, spontaneous homologous recombination can restore genotype to wild type in mouse iPS cells heterozygous for genetic mutations. Through genome editing, the clinical application of patient‐specific genetic mutation‐free iPS cells to genetic disorders can finally be realized.